Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report)’s stock price dropped 10.1% on Tuesday . The stock traded as low as $1.12 and last traded at $1.16. Approximately 658 shares traded hands during trading, a decline of 80% from the average daily volume of 3,357 shares. The stock had previously closed at $1.29.
Vaccinex Stock Performance
The stock has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.06. The stock has a market capitalization of $3.02 million, a price-to-earnings ratio of -0.02 and a beta of 1.10.
Vaccinex Company Profile
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Featured Stories
- Five stocks we like better than Vaccinex
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
